Comment on “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
- 5 December 2019
- journal article
- letter
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 59 (2) , 281-282
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?Clinical Pharmacokinetics, 2019
- Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug ProductsJournal of Pharmaceutical Sciences, 2018
- A comparison of the intrasubject variation in drug exposure between generic and brand‐name drugs: a retrospective analysis of replicate design trialsBritish Journal of Clinical Pharmacology, 2016
- Thyroxine: anatomy of a health scareBMJ, 2009
- Requirements for generic anti-epileptic medicines: a regulatory perspectiveJournal of Neurology, 2009
- Psychological well‐being in patients on ‘adequate’ doses of l‐thyroxine: results of a large, controlled community‐based questionnaire studyClinical Endocrinology, 2002
- Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalenceStatistics in Medicine, 2000
- Some statistical considerations on the FDA draft guidance for individual bioequivalenceStatistics in Medicine, 2000
- Individual Bioequivalence—A Review of the FDA Draft GuidanceDrug Information Journal, 1999